Specialty Pharmacy

Sofosbuvir, velpatasvir, and voxilaprevir successful in patients with hepatitis C virus infection, with and without HIV co-infection, including those with prior noncompletion of treatment or poor adherence to direct-acting antiviral drug regimens.

Former New York Giants running back Tiki Barber discusses his mother's fight against breast cancer and his advocacy for cancer awareness.

The epidemiology of hepatitis A has shifted from point-source outbreaks to outbreaks caused by person-to-person transmission.

Top news of the day from across the health care landscape

Ron Lanton III, Esq., executive director and senior counsel for Frier Levitt Government Affairs, discusses how the growing number of PBM-owned specialty pharmacies could impact the pharmacy industry.

People who inject drugs may still able to achieve a cure of hepatitis C virus infection with treatment with direct-acting antivirals.

Testing DNA through plasma or urine rather than tissue offers health care providers an alternative method to evaluate potential treatment resistance.

The FDA approved Merck’s pembrolizumab (Keytruda) for the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib.

Revefenacin (Yupelri, Theravance Biopharma and Mylan) is the first once-daily, long-acting nebulized bronchodilator for the treatment of chronic obstructive pulmonary disease.

If approved, avatrombopag (Doptelet) would also be indicated for the treatment of chronic immune thrombocytopenia in patients who have had insufficient response to a previous therapy.

Top news of the day from across the health care landscape

Top news of the week from Specialty Pharmacy Times.

New data presented at the 2018 ACR/ARHP Annual Meeting shows that the treatment regimens for many patients are not being changed to reach a “treat-to-target” goal for low disease activity.

A look at last week's top stories in the world of pharmacy.

An up-to-date analysis of melanoma mortality rates show that deaths among men are rising, but stabilizing or decreasing in women.

Top news of the day from across the health care landscape.

Selinexor is indicated for patients with previously treated diffuse large B-cell lymphoma who are ineligible to receive high-dose chemotherapy with stem cell rescue or CAR T-cell therapy.

Interferon lambda 4 represents a vulnerability that benefits hepatitis C virus to the detriment of humans.

Seattle Genetics submitted an application for the expanded use of brentuximab vedotin (Adcetris) in combination with a chemotherapy regimen for patients with peripheral T-cell lymphoma.

Prescriptions for hormonal therapy medications increased in states that expanded Medicaid, according to a recent analysis.

Top news of the day from across the health care landscape.

Treatment regimens consisting of daclatasvir plus sofosbuvir plus ribavirin and velpatasvir/sofosbuvir plus ribavirin show similar cure rates in patients with hepatitis C virus genotype 2 and 3.

Elotuzumab (Empliciti) with pomalidomide and dexamethasone (Pd) is the first triplet combination to be approved based on a randomized clinical trial using Pd as a comparator.

If approved for this indication, dupilumab (Dupixent) will be the first systemic biologic medicine to treat adolescents with moderate-to-severe atopic dermatitis.

Targeting interleukin (IL)-17A and IL-22 proteins may help delay the development of hepatic fibrosis.

Top news of the day from across the health care landscape.

Stigma may cause undiagnosed individuals with HIV to go unidentified and fail to get quality care and treatment.

With the growth of specialty medications and the high-touch care that is needed to ensure optimal outcomes, a niche market focused on providing ancillary services for these drugs has grown in popularity.

Ron Lanton III, Esq., executive director and senior counsel for Frier Levitt Government Affairs, discusses the key components of the American Patients First drug pricing blueprint and how the plan could affect specialty pharmacy.

Officials with the FDA have approved a new opioid, (Dsuvia, AcelRx Pharmaceuticals), sparking some controversy in the media that the opioid has potential for abuse.